HC Wainwright Estimates Immunic’s Q4 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at HC Wainwright issued their Q4 2024 earnings estimates for shares of Immunic in a note issued to investors on Monday, November 25th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.25) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.93) per share.

IMUX has been the topic of several other reports. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Leerink Partners reissued an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. Finally, B. Riley initiated coverage on shares of Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Immunic presently has an average rating of “Buy” and a consensus price target of $11.80.

Immunic Price Performance

NASDAQ IMUX opened at $1.14 on Tuesday. The company’s 50 day simple moving average is $1.38 and its 200 day simple moving average is $1.34. Immunic has a 12 month low of $0.97 and a 12 month high of $2.11. The company has a market capitalization of $102.69 million, a P/E ratio of -0.93 and a beta of 1.88.

Institutional Investors Weigh In On Immunic

Several institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in Immunic during the 1st quarter worth approximately $25,000. Jane Street Group LLC boosted its stake in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. State Street Corp boosted its stake in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the last quarter. Finally, Ikarian Capital LLC boosted its stake in Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Insider Transactions at Immunic

In related news, Director Richard Alan Rudick acquired 87,300 shares of the stock in a transaction on Tuesday, November 12th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now owns 87,300 shares of the company’s stock, valued at $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.00% of the stock is owned by insiders.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.